IL2 and Hyperglycemia: In contrast to the assumption that ultra-low dose IL-2 treatment causes a better glycemic control than low dose IL-2, we found that low dose IL-2 resulted in lower blood glucose levels than uIL-2 did (Fig. 5A), and only 50% of low dose IL-2 treated mice developed hyperglycemia compared with 100% in uIL-2 group (Fig. 5B).